Regeneron Pharmaceuticals SG&A decreased by 16.4% to $647.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.3%, from $633.00M to $647.70M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 10.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $414.70M | $445.00M | $559.60M | $450.00M | $476.30M | $529.10M | $660.50M | $601.10M | $652.00M | $640.50M | $737.70M | $689.00M | $758.80M | $714.40M | $792.20M | $633.00M | $634.20M | $657.80M | $775.00M | $647.70M |
| QoQ Change | — | +7.3% | +25.8% | -19.6% | +5.8% | +11.1% | +24.8% | -9.0% | +8.5% | -1.8% | +15.2% | -6.6% | +10.1% | -5.9% | +10.9% | -20.1% | +0.2% | +3.7% | +17.8% | -16.4% |
| YoY Change | — | — | — | — | +14.9% | +18.9% | +18.0% | +33.6% | +36.9% | +21.1% | +11.7% | +14.6% | +16.4% | +11.5% | +7.4% | -8.1% | -16.4% | -7.9% | -2.2% | +2.3% |
Range$414.70M – $792.20M
CAGR+9.8%
Avg YoY Growth+10.8%
Median YoY Growth+13.2%
SG&A at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's sg&a?
- Regeneron Pharmaceuticals (REGN) reported sg&a of $647.70M in Q1 2026.
- How has Regeneron Pharmaceuticals's sg&a changed year-over-year?
- Regeneron Pharmaceuticals's sg&a increased by 2.3% year-over-year, from $633.00M to $647.70M.
- What is the long-term trend for Regeneron Pharmaceuticals's sg&a?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's sg&a has grown at a 10.3% compound annual growth rate (CAGR), from $1.82B to $2.70B.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.